Eagle Pharmaceuticals Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Date | Value | Name | Entity | Role | Shares | Max Price |
---|---|---|---|---|---|---|
16 May 23 | SellUS$299,700 | Scott Tarriff | Individual | 15,000 | US$19.98 | |
15 May 23 | SellUS$930,656 | Scott Tarriff | Individual | 45,000 | US$21.52 |
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
Private Companies | 6,841 | 0.0527% |
General Public | 17,201 | 0.132% |
VC/PE Firms | 1,061,509 | 8.17% |
Individual Insiders | 1,533,551 | 11.8% |
Institutions | 10,367,869 | 79.8% |
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
1,453,244 | US$7.4m | 1.88% | no data | |||
1,061,509 | US$5.4m | 0% | 2.19% | |||
984,908 | US$5.0m | 10.8% | no data | |||
775,525 | US$3.9m | -32% | no data | |||
745,080 | US$3.8m | -34.3% | 0.03% | |||
638,124 | US$3.2m | -0.85% | no data | |||
522,402 | US$2.7m | 50.3% | no data | |||
493,546 | US$2.5m | 74.4% | no data | |||
391,758 | US$2.0m | -4.16% | no data | |||
294,450 | US$1.5m | 15% | no data | |||
287,555 | US$1.5m | 21.4% | no data | |||
258,677 | US$1.3m | 94% | no data | |||
246,497 | US$1.3m | -12.2% | no data | |||
246,425 | US$1.3m | 0% | 0.06% | |||
225,295 | US$1.1m | 2.48% | no data | |||
222,594 | US$1.1m | 7.13% | no data | |||
222,017 | US$1.1m | 886% | no data | |||
217,668 | US$1.1m | 0% | no data | |||
207,614 | US$1.1m | 535% | no data | |||
186,631 | US$948.1k | 3,910% | no data | |||
176,361 | US$895.9k | 0% | no data | |||
172,482 | US$876.2k | 20.9% | no data | |||
163,490 | US$830.5k | 48.6% | no data | |||
143,826 | US$730.6k | 0% | no data | |||
128,697 | US$653.8k | 124% | no data |